Ignite Creation Date:
2024-05-05 @ 12:09 PM
Last Modification Date:
2024-10-26 @ 9:21 AM
Study NCT ID:
NCT00261079
Status:
COMPLETED
Last Update Posted:
2007-11-07
First Post:
2005-12-01
Brief Title:
Fexofenadine in Pruritic Skin Disease
Sponsor:
Handok Inc
Organization:
Handok Inc
Study Overview
Official Title:
The Evaluation of Efficacy and Safety of Fexofenadine 180mg Tablets for 7 Days in the Treatment of Pruritic Skin Disease
Status:
COMPLETED
Status Verified Date:
2007-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Primary objective
To compare the efficacy and safety profile of Fexofenadine 180mg tablets plus prednicarbate25mgg vs prednicarbate25mgg alone in the treatment of pruritic skin disease
Secondary objective
To evaluate patients satisfaction of Allegra treatment
To compare the efficacy and safety profile of Fexofenadine 180mg tablets plus prednicarbate25mgg vs prednicarbate25mgg alone in the treatment of pruritic skin disease
Secondary objective
To evaluate patients satisfaction of Allegra treatment
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None